Transportation
NHS Rolls Out £1.7 Million Gene Therapy for Sickle Cell Disease
- Health service in England agrees discount for Vertex’s Casgevy
- Drug already available for some patients with beta-thalassemia
This article is for subscribers only.
One of the world’s most expensive medicines will be used to treat some patients with sickle cell disease in England using the state-funded National Health Service.
The one-time gene-editing therapy Casgevy, developed by Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG, has a list price of £1.7 million ($2.1 million), but England’s drug cost regulator said it has negotiated a lower, undisclosed price.